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1. Introduction
  Myocardial ischemia/reperfusion injury is a common 
pathological and physiological course of myocardial 
reperfusion seen in the clinical practice and affects 
the post-ischemic recovery of the heart function, 
even endangering patients’ lives[1]. The mitochondrial 
permeability transition pore (mPTP) acts as a key target 
organ of the mid- and down-stream ischemia/reperfusion 
injury pathways. Intracellular calcium overload and 
ischemia/oxygenation-induced free radicals serve as the 
underlying mechanism of myocardial ischemia/reperfusion 
injury, eventually resulting in increased intracellular 
mPTP permeability and thereby leading to cell death by 
activating the mitochondrial apoptotic pathway[2-6]. The 
ischemia/reperfusion injury can be significantly alleviated 
by inhibiting the opening of mPTPs. Until now, an adequate 
evidence has demonstrated that cyclosporin A (CsA), an 
mPTP inhibitor, effectively alleviates ischemia/reperfusion 
injury. However, the CsA doses used in previous studies 
varied considerably, and its inhibitory effects on myocardial 
injury were also inconsistent. In this study, we observed the 
dose-effect relationship of different CsA doses in vivo using 
a rat model of ischemia/reperfusion injury and determined 
the optimal dose. 
Objective: To investigate the protective effect of different cyclosporin A (CsA) doses on 
myocardial ischemia/reperfusion injury in rat models. Methods: A rat model of myocardial 
ischemia/reperfusion injury was established in vivo and the rats were randomly divided into four 
groups: placebo (PBS; T1), low-dose (CsA dose: 1.0 mg/kg; T2), medium-dose (CsA dose: 
2.5 mg/kg; T3), and high-dose (CsA dose: 5.0 mg/kg; T4) groups. Heart function indexes were 
monitored at different time points, the extent of myocardial infarction was assessed by Evans 
Blue-TTC staining, and creatine kinase MB mass and cardiac troponin I values were measured 
by biochemical assays. Results: Compared with the T1 and T2 groups, both the creatine kinase 
MB mass and cardiac troponin I were significantly lower in the T3 and T4 groups (P<0.05). The 
mean arterial pressure (MAP) and left ventricular systolic pressure (LVSP) decreased sequentially 
in each group, with the extending reperfusion time. Significant decreases in LVSP and MAP were 
observed in the T3 and T4 groups as compared to the T1 and T2 group (P<0.05), and the T2 group 
showed a significantly lower LVSP and MAP decline than the T1 group (P<0.05). Compared with 
the T1 group, the rats from the T2, T3, and T4 groups suffered from a significantly lower extent 
of myocardial infarction (P<0.05). Also, the animals in the T3 and T4 groups had a significantly 
smaller extent of myocardial infarction than those in the T2 group (P<0.05). Conclusions: Various 
CsA doses exert different degrees of protection against ischemia/reperfusion injury, and this 
protective effect peaks at approximately 2.5 mg/kg in rat models.
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2. Materials and methods
2.1. Rat grouping
  In total, 32 healthy male Sprague Dawley (SD) rats, weighing 
300-320 g, were provided by Dongchuang Laboratory 
Animals with the certificate number SCXK (Xiang) 2009-0012 
(Changsha, Hunan, China). The rats were randomly assigned 
into four groups: placebo group (PBS; T1 group), low-dose 
group (CsA dose: 1.0 mg/kg; T2 group), medium-dose group 
(CsA dose: 2.5 mg/kg; T3 group), and high-dose group (CsA 
dose: 5.0 mg/kg; T4 group), eight in each group. 
2.2. Main instruments and reagents
  The instruments and reagents used in this study included 
an artificial respiration machine for animals (Huaibei 
Zhenghua Bioinstrumentation Co., Ltd., Anhui, China); a 
HITACHI 7080 automatic biochemical analyzer (HITACHI, 
Japan); a Beneview T5 monitor (Mindray); microcatheter 
(EchelonTM 10 microcatheter); CsA, Evans-Blue, 2,3,5-
triphenyltetrazolium chloride (TTC, Sigma, U.S.), cardiac 
troponin 栺 (cTn栺), and creatine kinase MB (CK-MB, 
Nanjing Jiancheng Bioengineering Institute, China). 
2.3. Establishment of ischemia/reperfusion injury model
  Ischemia/reperfusion injury model was established 
through the ligation of anterior descending branch of 
left coronary artery[7]. The animals were anesthetized 
using 1% pentobarbital sodium (40 mg/kg). A catheter was 
subsequently placed inside the trachea and connected 
to a breathing machine. First, the rats were sterilized by 
iodophor after removing the hair from the chest skin, and 
the skin above the heart was then incised along the left side 
of the sternum, with a vertical 2.0-2.5 cm cut. Subcutaneous 
tissues and muscles were detached to expose the left 3rd 
to 4th ribs until the shadow of the beating heart was seen. 
Subsequently, a bent-head hemostasis clamp was rapidly 
inserted into the thorax, in the gap between the 3rd and 4th 
ribs, and the thorax area was fully exposed. After the chest 
was opened, the bottom part of the heart was thoroughly 
exposed and the pericardium was removed with a forceps 
used in ocular surgery. The heart was gently pushed 
rightwards using a wet cotton swab, the thymus and left atria 
were slightly lifted with a cotton stick, and the vena cava 
was exposed between the left atria and pulmonary artery. 
The vein was used as the ligation sign. The left coronary 
artery was ligated by No. 3/8 sutures at 1-2 mm around 
the root of the left atria with a depth of 1.0-1.5 mm, and 
the anterior descending branch of the left coronary artery 
was ligated along with the vena cava. Prior to ligation, 
two No. 2 suture strings were placed below the ligatures 
for unknotting[8]. After ligation of the coronary artery, the 
heart was immediately placed back into the thorax, the 
thorax was gently pressed to squeeze out the gas, and it was 
subsequently closed by a vessel clamp. The ischemia time 
was 30 min and the reperfusion time was 2 h. Criteria for a 
successful left anterior descending (LAD) blockage were a 
high-frequency QRS complex, a significantly elevated ST 
segment, and the darkening of the myocardial color under 
the ligatures. Criteria for successful reperfusion were a 
dropping QRS complex or a significant decline of the ST 
segment, and the red appearance of the myocardial muscle 
below the ligatures. 
2.4. Measurements of blood flow dynamics
  Prior to the ischemia, at the beginning of the reperfusion 
(0 min) and 30, 60, 90, and 120 min afterwards, the heart 
rate (HR), left ventricular systolic pressure (LVSP), and 
left ventricular developed pressure (LVDP) were recorded 
by a monitor and the mean arterial pressure (MAP) were 
calculated. 
2.5. Measurement of the biochemical markers for myocardial 
injury 
  After reperfusion, 3 mL of jugular venous blood was 
collected in a 5 mL syringe and injected into a biochemical 
tube and a tube for the myocardial calcium protein assay, 
respectively. After centrifugation at 2 000 r/min for 10 min, 
the serum was prepared for subsequent analysis. 
2.6. Evaluation on the extent of myocardial infarction
  Following reperfusion and blood sampling, the anterior 
descending branch of the left coronary artery was repeatedly 
ligated and stained by the Evans Blue-TTC method. The 
weight of the left ventricle myocytes and that of the necrotic 
myocytes were determined using an electronic balance. The 
degree of ischemia, expressed as the weight of the necrotic 
myocytes as a proportion by weight of the left ventricle 
myocytes, was then calculated. 
2.7. Statistical analysis
  The SPSS 17.0 statistical software was used for statistical 
analysis. Measurement data were expressed as mean依
standard deviation. The dynamics of the blood flow, as data 
from repeated measurements, were statistically analyzed by 
ANOVA. Group comparisons were performed by the LSD test. 
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A value of P<0.05 was considered as statistically significant. 
3. Results
3.1. Comparison of CK-MB and cTnI between groups
  The CK-MB mass was significantly lower in the T2, T3, 
and T4 groups than in the T1 group (P<0.05). The CK-MB 
mass was significantly lower in the T3 and T4 groups than 
in the T1 group (P<0.05). The T3 and T4 groups differed in 
the CK-MB mass, but the difference did not reach statistical 
significance (Table 1). The cTnI value was significantly lower 
in the T2, T3, and T4 groups than in the T1 group (P<0.05). 
Albeit the T2, T3, and T4 groups differed regarding cTn栺, 
the differences did not reach statistical significance (Table 
1). 
Table 1
Effect of CsA on CK-MB and cTn栺 in the rat model of myocardial 
ischemia/reperfusion injury.
Group (n=8) CK-MB (U/mL) cTn栺 (ng/mL)
Placebo group 125.38依5.85a 12.98依1.29a
Low-dose group (1.0 mg/kg CsA) 109.79依4.27b   9.38依1.08b
Medium-dose group (2.5 mg/kg CsA)   99.83依4.60c   8.53依0.84b
High-dose group (5.0 mg/kg CsA)   98.24依4.60c   8.35依0.86b
The data are expressed as mean依SD. Means followed by differnt 
letters are significantly different at the 0.05 level by the LSD test.
3.2. Comparison of HR between groups
  Prior to the ligation of the coronary artery, the HR did not 
differ between the groups. After ligation, the HR declined 
to various extents in all groups. There was no statistical 
significance between the different groups (Table 2). 
3.3. Comparison of MAP groups
  Prior to ligation, no significant differences were noted 
in the baseline MAP, whereas the values decreased to 
different degrees at the beginning of the reperfusion, and 
30, 60, 90, and 120 min later. No statistical significance 
was seen in terms of MAP at any time point between the 
T3 and T4 groups. Pair-comparisons between other groups 
revealed statistically significant differences (P<0.05). The 
MAP declined to a lesser extent in the T3 and T4 groups as 
compared to that in the T1 and T2 groups (P<0.05), and the 
extent of MAP decrease in the T2 group was significantly 
smaller than that in the T1 group (P<0.05) (Table 2). 
3.4. Comparison of LVSP between groups
  No significant differences were noted before ligation in 
the baseline LVSP, whereas the MAP decreased to different 
degrees at the beginning of reperfusion and 30, 60, 90, and 
120 min later. No statistically significant changes in LVSP 
were visualized at any time point in the T3 and T4 groups. 
Pair-comparisons among other groups revealed a statistically 
significant difference in the LVSP (P<0.05). The LVSP values 
declined to significantly lower levels in the T3 and T4 groups 
as compared to that in the T1 and T2 groups (P<0.05), and 
the extent of LVSP decrease in the T2 group was significantly 
smaller than that in the T1 group (P<0.05)(Table 2). 
Table 2
Effect of CsA on the dynamics of blood flow in the rat model of myocardial ischemia/reperfusion injury.
Index Group Prior to ligation
Time post reperfusion (min)
0 30 60 90 120
HR (beats/min)    T1     423.3±18.1  325.6±15.8  351.4±12.1  321.2±13.1  305.3±13.7   300.3±11.8
   T2     421.5±16.5  331.6±12.2  349.3±14.7  320.7±14.1  309.0±14.0   307.3±11.4
   T3     420.1±10.3  329.0±13.1  349.5±14.5  320.2±16.6  314.2±10.3 307.1±8.1
   T4     421.8±13.7  329.3±12.4  350.2±13.4        320.7±9.2  314.4±10.2 309.5±8.0
MAP   (mmHg)    T1   108.2±5.5   86.6±5.9c   76.0±4.8c   65.4±8.2c   58.1±7.1c   57.1±4.9c
   T2   111.3±6.4   91.5±3.8b   83.5±3.5b   74.3±5.3b   67.2±6.0b   63.0±5.5b
   T3   110.0±6.2   95.6±6.3a   87.4±5.8a   81.5±6.1a   79.7±5.4a   78.2±5.7a
   T4   107.2±4.6   96.3±6.2a   86.7±5.6a   81.6±6.3a   81.3±4.3a   80.4±3.9a
LVSP   (mmHg)    T1   139.4±4.5 120.3±5.3c 124.6±3.2c 123.4±3.6c 124.3±3.5c 123.4±3.1c
   T2   139.3±4.1 129.2±4.0b 129.5±2.3b 128.5±4.3b 128.7±4.7b 128.1±6.4b
   T3   138.8±3.7 134.0±2.8a 135.4±3.0a 135.7±2.3a 136.1±3.2a 134.4±4.2a
   T4   137.1±4.7 135.6±2.8a 135.6±2.7a 134.0±3.5a 132.2±2.5a 133.0±3.1a
The data are expressed as mean依SD. T1, T2, T3 and T4 represent the placebo group, low-dose group (1.0 mg/kg CsA), medium-dose group (2.5 
mg/kg CsA) and high-dose group (5.0 mg/kg CsA), respectively. HR: Hear rate; MAP: Mean arterial pressure; LVSP: Left ventricular systolic 
pressure. Means followed by differnt letters are significantly different at the 0.05 level by the LSD test.
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3.5. Comparison of the extent of myocardial infarction 
between groups
  The extent of myocardial ischemic/reperfusion injury in all 
groups was 45.00%依2.07%, 35.29%依1.52%, 29.05%依2.08%, and 
26.90%依1.86%, respectively. The values in the T2, T3, and T4 
groups were significantly smaller than that in the T1 group 
(P<0.05), and the extent of myocardial ischemia/reperfusion 
injury in the T3 and T4 groups was significantly lower than 
that in the T2 group (P<0.05). The T3 and T4 groups differed 
in terms of this parameter, but the difference did not reach 
statistical significance, as illustrated in Figure 1. 
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Figure 1. Effect of CsA on the extent of myocardial infarction in the 
rat model of myocardial ischemia/reperfusion injury. 
T1, T2, T3 and T4 represent the placebo group, low-dose group (1.0 
mg/kg CsA), medium-dose group (2.5 mg/kg CsA) and high-dose 
group (5.0 mg/kg CsA), respectively. Means marked by differnt letters 
are significantly different at the 0.05 level by the LSD test.
4. Discussion
  Worldwide, acute myocardial infarction has dramatically 
high mortality rates. The extent of the infarcted cardiac 
area is closely correlated with the mortality that occurs as 
a result of this condition. Therefore, reducing the extent 
of myocardial infarction is a key task and therapeutically 
important goal[9]. Coronary artery intervention can restore 
the blood flow in ischemic tissues and alleviate the severity 
of acute myocardial infarction[10]. However, a more serious 
consequence, reperfusion injury, may be induced when the 
blood flow through the coronary arteries is subsequently 
restored[11]. Previous studies using animal models of acute 
myocardial infarction suggested that reperfusion injury 
is likely to cause 50% of the myocardial infarction[12,13]. 
Consequently, the development of approaches that could 
alleviate reperfusion injury following interventional therapy, 
to reduce the extent of myocardial infarction and to improve 
prognosis, becomes a new and important direction for 
clinicians.
  Previous studies also proposed new strategies to target 
ischemic/reperfusion injury. Self-adaptation, the ability 
of heart for endogenous protection, has been deemed to 
decrease the incidence of coronary heart disease, mitigate 
the severity of myocardial infarction, improve myocardial 
contraction, and enhance clinical prognosis. At present, it 
is suggested that pre- and post-ischemia adaptation plays 
a role in myocardial reperfusion via a common signaling 
pathway. The use of therapeutic approaches that act on 
related elements of this signaling pathway were shown to 
protect the myocytes similarly to the way pre- and post-
ischemic adaptation do[14]. Therefore, the concept of post-
medication adaptation was proposed. According to this 
concept, therapeutic drugs could alleviate the extent of 
myocardial infarction during myocardial reperfusion by 
activating the reperfusion injury salvage kinase (RISK) 
pathway, consisting of a variety of kinases involved in 
protecting the heart from reperfusion injury[15]. At the same 
time, mPTP was discovered as another vital target of the 
downstream pathway. An additional evidence supported the 
idea that the protective effects of pre- and post-ischemia 
adaptation on the heart are mediated by RISK-mPTP 
pathway[15]. Consequently, mPTP is viewed as a vital target 
of pharmacological therapies. Moreover, post-ischemic 
adaptation avoids the need for invasive interventions, and 
it can therefore easily be applied during the treatment 
of patients with acute myocardial infarction undergoing 
reperfusion therapy and, additionally, it is easy to be 
performed.
  mPTP is a non-specific channel whose changes in 
permeability may facilitate the entry of protons and that 
of certain molecules and solutes under 1 500 Da through 
the inner mitochondrial membrane. This reduces the 
mitochondrial membrane potential and, coupled with 
the decrease in oxidative phosphorylation, leads to ATP 
deficiency, swollen mitochondria, and cellular apoptosis. 
CsA, as a specific mPTP inhibitor, is able to inhibit the opening 
of mPTP and plays a vital role in preventing and alleviating 
the incidence of ischemia/reperfusion injury. Although it has 
been convincingly proven that CsA protects the myocytes 
by blocking the opening of mPTP at the risk of ischemic/
reperfusion injury, there have been no studies to validate 
the dose-effect relationship and to identify the optimal CsA 
dose. It has been merely confirmed by in vitro models that 
low-dose cyclosporin (0.5-2.0 毺mol/L) exerts protective 
effects and that this protection is lost at doses >5 毺mol/L[16]. 
Skyschally et al. conducted ischemia/reperfusion injury 
experiments in mammalian models using a dose of 5 mg/kg 
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and showed that the extent of myocardial infarction in the 
CsA and control groups was approximately 25% and 45%, 
respectively[17]. Pagel and Krolikowski delivered a 5 mg/kg 
dose of cyclosporin in rabbit models and observed findings 
that are inconsistent with those from previous studies[18]. A 
number of investigations utilized different doses and yielded 
disparate conclusions. CsA, as an immunosuppressant, 
poses potential harm after its long-term use, including renal 
and liver toxicities, and also increases the susceptibility for 
infections and carcinomas. Intravenously delivered CsA has 
been mainly used for organ transplant recipients to prevent 
rejection, and the dose is generally less than 5 mg/kg. 
Gomez et al reviewed previous studies and found that a dose 
of <5 mg/kg of CsA did not hurt the dynamics of blood flow 
or cause alternative toxicities[19]. 
  This study demonstrated that various CsA doses exert 
different protective effects on ischemia/reperfusion injury. 
The protective effect of CsA peaks at a certain dose, and we 
found this optimal dose, at which the best protective effects 
are observed, to be approximately 2.5 mg/kg.
Conflict of interest statement
  We declare that we have no conflict of interest.
Acknowledgments
  
  This study was financially supported by the Key Science 
and Technology Project of Haikou City, with grant number 
2011-0142.
References
[1]   Aronow WS. Epidemiology, pathophysiology, prognosis, and 
treatment of systolic and diastolic heart failure. Cardiol Rev 2006; 
14(3): 108-124.
[2]   Li Q, Zhou LY, Gao GF, Jiao JQ, Li PF. Mitochondrial network in 
the heart. Protein Cell 2012; 3(6): 410-418.
[3]   Pott C, Eckardt L, Goldhaber JI. Triple threat: the N+/Ca2+ exchanger 
in the pathophysiology of cardiac arrhythmia, ischemia and heart 
failure. Curr Drug Targets 2011; 12(5): 737-747.
[4]   Halestrap AP. What is the mitochondrial permeability transition 
pore? J Mol Cell Cardiol 2009; 46: 821-831.
[5]   Webster KA. Mitochondrial membrane permeabilization and cell 
death during myocardial infarction: Roles of calcium and reactive 
oxygen species. Future Cardiol 2012; 8(6): 863-884.
[6]   Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic 
peptide administered just prior to reperfusion limits infarction in 
rabbit hearts. Basic Res Cardiol 2006; 101(4): 311-318.
[7]   Li J, Zhang HF, Wu F, Nan Y, Ma H, Guo W, et al. Insulin inhibits 
tumor necrosis factor-α induction in myocardial ischemia/
reperfusion: Role of Akt and endothelial nitric oxide synthase 
phosphorylation. Crit Care Med 2008; 36(5): 1551-1558.
[8]   Zhou XW, Liao ZF, Chen J, Liu LM. Establishment and evaluation 
of myocardial ischemia reperfusion injury in rats. Lab Anim Comp 
Med 2009; 29(4): 223-232.
[9]   Rodríguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. 
Reperfusion injury as a therapeutic challenge in patients with 
acute myocardial infarction. Heart Fail Rev 2007; 2(3-4): 207-
216.
[10] van Domburg RT, Sonnenschein K, Nieuwlaat R, Kamp O, Storm CJ, 
Bax JJ, et al. Sustained benefit 20 years after reperfusion therapy 
in acute myocardial infarction. J Am Coll Cardiol 2005; 46(1): 15-
20.
[11] Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, 
et al. Determinants of 6-month mortality in survivors of myocardial 
infarction after thrombolysis. Results of the GISSI-2 data base. 
The Ad hoc Working Group of the Gruppo Italiano per lo Studio 
della Sopravvivenza nell’Infarto Miocardico (GISSI)-2 Data Base.
Circulation 1993; 88(2): 416-429.
[12] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus 
intravenous thrombolytic therapy for acute myocardial infarction: 
A quantitative review of 23 randomised trials. Lancet 2003; 
361(9351):  13-20.
[13] Braunwald E, Kloner RA. Myocardial reperfusion: A double-edged 
sword? J Clin Invest 1985; 769(5): 1713-1719.
[14] Vinten-Johansen J. Postconditionig: A mechanical maneuver that 
triggers biological and molecular cardioprotective responses to 
reperfusion. Heart Fail Rev 2007; 12(3-4): 235-244.
[15] Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, et al. MG53 participates 
in ischaemic postconditioning through the RISK signalling 
pathway. Cardiovasc Res 2011; 91: 108-115.
[16] Nazareth W, Yafei N, Crompton M. Inhibition of anoxia-induced 
injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol 
1991; 23(12): 1351-1354.
[17] Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion 
reduces infarc size in pigs. Cardiovasc Drugs Ther 2010; 24(1): 
85-87.
[18] Pagel PS, Krolikowski JG. Transient metabolic alkalosis during 
early reperfusion abolishes helium preconditioning against 
myocardial infarction: Restoration of cardioprotection by 
cyclosporin A in rabbits. Anesth Analg 2009; 108(4): 1076-1082.
[19] Gomez L, Li B, Mewton N, Sanchez I, Piot C, Elbaz M, et al. 
Inhibition of mitochondrial permeability transition pore opening: 
translation to patients. Cardiovas Res 2009; 83(2): 226-233.
